How to Test for Hashimoto's Thyroiditis: A Complete Diagnostic Guide

What Is Hashimoto's Thyroiditis and Why Does Testing Matter?

Hashimoto's thyroiditis is the most common cause of hypothyroidism in iodine-sufficient countries like the United States. The immune system produces antibodies that attack thyroid tissue, gradually reducing hormone output over months or years. Testing confirms the autoimmune origin of a low or borderline TSH, separating Hashimoto's from other causes of thyroid dysfunction.

Without accurate diagnosis, patients may receive treatment aimed at symptoms alone rather than the underlying autoimmune process. Identifying Hashimoto's also flags elevated risk for other autoimmune conditions, including type 1 diabetes, celiac disease, and rheumatoid arthritis. A 2021 review in the journal Thyroid confirmed that Hashimoto's patients have a statistically significant increased prevalence of concurrent autoimmune disorders compared with the general population.

Why Hashimoto's Is Frequently Missed

The disease progresses silently for years. TSH may stay within the normal reference range for a decade while autoimmune damage accumulates. Symptoms like fatigue, brain fog, cold intolerance, and weight gain overlap with dozens of other conditions, so providers sometimes attribute them to stress or depression. A single normal TSH result does not rule out early Hashimoto's.

Who Should Get Tested

The American Thyroid Association recommends testing for thyroid dysfunction in patients who have:

• A personal or family history of thyroid disease
• Symptoms consistent with hypothyroidism (fatigue, constipation, dry skin, cold sensitivity)
• Another autoimmune condition already diagnosed
• Unexplained infertility, miscarriage, or menstrual irregularity
• A goiter (enlarged thyroid) detected on physical exam
• Prior neck radiation

Women over 60 or anyone with a first-degree relative who has Hashimoto's should discuss routine screening with their clinician even in the absence of symptoms.

The Core Blood Tests for Hashimoto's

The three blood tests that together confirm Hashimoto's are TSH, TPO antibody, and thyroglobulin antibody. No single result alone makes the diagnosis, but the combination of an abnormal TSH plus a positive TPO antibody is considered diagnostic in most guidelines.

TSH (Thyroid-Stimulating Hormone)

TSH is always the first test ordered. Produced by the pituitary gland, TSH rises when the thyroid underperforms, because the pituitary tries to stimulate more hormone output. A TSH above 4.0 mIU/L (using the most common laboratory reference range) suggests hypothyroidism. In Hashimoto's, TSH may be mildly elevated, frankly elevated, or even transiently low during the "Hashitoxicosis" phase when damaged follicles dump stored hormone.

The 2017 ATA Clinical Practice Guidelines for Hypothyroidism in Adults state: "Serum TSH should be the initial test for diagnosis of primary hypothyroidism." This makes TSH the gateway test before antibody panels are added.

A TSH level alone cannot distinguish Hashimoto's from other causes of hypothyroidism. That distinction requires antibody testing.

Free T4 (Thyroxine)

Ordering free T4 alongside TSH shows how far thyroid function has declined. Free T4 below the lab reference (typically <0.8 ng/dL) alongside an elevated TSH indicates overt hypothyroidism. A normal free T4 with a mildly elevated TSH (4.0-10.0 mIU/L) is called subclinical hypothyroidism. Both patterns appear in Hashimoto's depending on disease stage.

Free T3 (Triiodothyronine)

Free T3 is not a first-line Hashimoto's diagnostic test, but clinicians sometimes add it when a patient remains symptomatic despite normal TSH and free T4 levels. Some individuals show impaired T4-to-T3 conversion, and a low free T3 may explain ongoing symptoms. The ATA does not recommend routine free T3 measurement for initial Hashimoto's diagnosis, but it becomes relevant during treatment optimization.

Antibody Tests: The Definitive Marker for Autoimmune Thyroid Disease

Antibody testing is the step that separates Hashimoto's from simple hypothyroidism. Two antibodies are clinically relevant.

Thyroid Peroxidase Antibody (TPO-Ab)

TPO-Ab is the most sensitive marker for Hashimoto's thyroiditis. A landmark study published in the Journal of Clinical Endocrinology and Metabolism (N=25,862) found TPO antibodies positive in approximately 95% of patients with confirmed Hashimoto's. Values above 35 IU/mL are generally considered positive, though the exact threshold varies by laboratory.

Higher TPO-Ab titers correlate with faster progression to overt hypothyroidism. One prospective cohort study found that women with TPO-Ab above 1,000 IU/mL progressed from subclinical to overt hypothyroidism at roughly twice the rate of women with titers between 35-500 IU/mL over a 5-year follow-up period. That data appears in a study indexed at PubMed.

Importantly, a positive TPO-Ab does not always mean a patient needs levothyroxine. Antibody positivity with a normal TSH is called "euthyroid Hashimoto's." These patients need monitoring, not immediate hormone replacement.

Thyroglobulin Antibody (TgAb)

TgAb is positive in roughly 60-80% of Hashimoto's cases. It is less sensitive than TPO-Ab, but ordering both panels together increases diagnostic yield. When TPO-Ab is negative but clinical suspicion remains high, a positive TgAb can still support the Hashimoto's diagnosis.

TgAb testing is also essential for thyroid cancer surveillance. Elevated TgAb interferes with thyroglobulin assays used to monitor differentiated thyroid cancer after thyroidectomy, so knowing a patient's TgAb status before any cancer workup matters clinically.

Interpreting Combined Antibody Results

| TPO-Ab | TgAb | Interpretation | |---|---|---| | Positive | Positive | Strongly supports Hashimoto's | | Positive | Negative | Supports Hashimoto's (typical pattern) | | Negative | Positive | Hashimoto's still possible; add ultrasound | | Negative | Negative | Hashimoto's less likely; seek other cause |

This framework guides the next step. When both antibodies are negative and TSH is elevated, the clinician should consider iodine deficiency, medication effects (lithium, amiodarone), or central hypothyroidism rather than assuming Hashimoto's.

Thyroid Ultrasound: When and Why to Use It

Ultrasound is not required for every Hashimoto's diagnosis, but it adds significant clarity when antibody results are equivocal or when a goiter or nodule is palpated on exam.

What the Ultrasound Shows

In Hashimoto's thyroiditis, a characteristic "heterogeneous echotexture" appears on grayscale imaging. The gland looks patchy and hypoechoic (darker than normal) due to lymphocytic infiltration and fibrosis. The gland may be enlarged early in the disease and atrophic in advanced disease. The ATA 2016 Thyroid Nodule Guidelines note that diffuse hypoechogenicity with or without a nodule is consistent with autoimmune thyroid disease.

A skilled ultrasonographer can identify these changes with high specificity. One meta-analysis of 16 studies found thyroid ultrasound had a pooled sensitivity of 79% and specificity of 82% for confirming Hashimoto's in antibody-equivocal cases. That analysis is available at PubMed.

When Ultrasound Is Specifically Indicated

• Both TPO-Ab and TgAb are negative but TSH remains elevated
• A palpable goiter is present
• A nodule is detected clinically or incidentally
• The patient has neck discomfort, pain, or visible asymmetry
• Cancer risk stratification is needed alongside the Hashimoto's diagnosis

Ultrasound does not replace blood tests. It adds structural information when functional and immunological data alone do not close the diagnostic loop.

Nodules Found During Ultrasound

Thyroid nodules occur in roughly 25-30% of the general adult population. Hashimoto's disease does not increase malignancy risk within nodules, but nodules discovered during a Hashimoto's workup still require standard ACR TIRADS or ATA risk stratification. Clinicians should not assume a nodule is benign simply because Hashimoto's is already confirmed.

Additional and Emerging Tests

Complete Thyroid Panel vs. Selective Ordering

Some telehealth providers offer a "complete thyroid panel" that includes TSH, free T4, free T3, TPO-Ab, TgAb, and reverse T3 in a single blood draw. The evidence base supporting reverse T3 measurement as a clinical decision-making tool is weak. The ATA explicitly states there is insufficient evidence to recommend routine reverse T3 testing in the initial evaluation of thyroid dysfunction. Ordering it may generate anxiety and additional unnecessary testing without changing management.

A focused panel of TSH plus TPO-Ab covers the diagnostic needs for most patients presenting with symptoms of hypothyroidism.

Thyroid Stimulating Immunoglobulin (TSI)

TSI testing is specific to Graves' disease, the autoimmune hyperthyroid condition. Ordering TSI makes sense when TSH is suppressed and hyperthyroid symptoms are present. It does not have a standard role in Hashimoto's diagnosis.

Anti-Nuclear Antibody (ANA) and Broader Autoimmune Screening

Because Hashimoto's clusters with other autoimmune diseases, some clinicians add ANA, anti-double-stranded DNA, or celiac serology (tissue transglutaminase IgA) when the clinical picture suggests a systemic autoimmune process. Roughly 5% of Hashimoto's patients have concurrent celiac disease, compared with approximately 1% of the general population. A 2019 systematic review published at PubMed confirmed this elevated association.

Broader autoimmune screening is not required for every Hashimoto's diagnosis but should be considered when gastrointestinal symptoms, joint pain, or other systemic features appear alongside thyroid dysfunction.

How to Read Your Thyroid Lab Results

Understanding raw numbers helps patients engage meaningfully with their clinicians. The following ranges reflect standard U.S. Laboratory reference intervals. Individual labs may vary slightly.

TSH Reference Ranges

| TSH Level | Interpretation | |---|---| | <0.4 mIU/L | Suppressed (possible hyperthyroidism or overmedication) | | 0.4-4.0 mIU/L | Normal | | 4.0-10.0 mIU/L | Subclinical hypothyroidism | | >10.0 mIU/L | Overt hypothyroidism; treatment strongly recommended |

The threshold for treating subclinical hypothyroidism in Hashimoto's remains debated. The 2017 ATA guidelines recommend treatment when TSH exceeds 10.0 mIU/L and suggest individualizing the decision when TSH is between 4.0-10.0 mIU/L based on symptoms, age, cardiovascular risk, and antibody status.

TPO-Ab Reference Ranges

Most U.S. Laboratories flag TPO-Ab as positive above 35 IU/mL. Some use a cutoff of 9 IU/mL or 34 IU/mL depending on the assay platform. Ask your lab which assay they use (Immulite, Roche Elecsys, or Abbott Architect are most common) because absolute titer comparisons between assays are not valid. Following trends on the same platform over time is more clinically meaningful than a single snapshot.

Free T4 and Free T3 Reference Ranges

Free T4 typically runs 0.8-1.8 ng/dL. Free T3 typically runs 2.3-4.2 pg/mL. Values at the low end of normal while TSH sits at the high end of normal may indicate early thyroid underperformance even before frank hypothyroidism develops.

The Diagnostic Sequence: Step-by-Step

1. Order TSH first. A single morning blood draw is sufficient. Fasting is not required, though some clinicians prefer fasting for consistency.
2. If TSH is abnormal (high or low) or clinical suspicion is strong despite a normal TSH, add free T4 and TPO-Ab to the same or next blood draw.
3. If TPO-Ab is positive, the Hashimoto's diagnosis is confirmed in the appropriate clinical context. Add TgAb if available.
4. If TPO-Ab is negative but suspicion remains, add TgAb and order a thyroid ultrasound.
5. If ultrasound shows heterogeneous echotexture consistent with Hashimoto's, the diagnosis stands even with seronegative antibodies. Seronegative Hashimoto's accounts for roughly 5% of cases.
6. Assess other autoimmune conditions if symptoms suggest a broader process.
7. Establish a monitoring schedule. Euthyroid Hashimoto's patients with positive antibodies and normal TSH should recheck TSH every 6-12 months. The ATA supports this monitoring interval.

How Hashimoto's Testing Differs for Special Populations

Testing During Pregnancy

Pregnancy changes TSH reference ranges significantly. The ATA recommends trimester-specific TSH targets: <2.5 mIU/L in the first trimester and <3.0 mIU/L in the second and third trimesters for women with known thyroid disease. The ATA 2017 Guidelines on the Management of Thyroid Disease During Pregnancy explicitly state that TSH should be measured in pregnant women with a personal history of thyroid disease, symptoms of hypothyroidism, or a prior pregnancy loss. TPO-Ab positivity in euthyroid pregnant women increases miscarriage risk, making antibody testing particularly meaningful in this population.

Testing in Adolescents

Hashimoto's is the most common cause of acquired hypothyroidism in children and teenagers. Goiter is a frequent presenting sign. Testing uses the same TSH and TPO-Ab approach as adults, though reference ranges differ slightly by age. The Pediatric Endocrine Society recommends against universal screening and favors targeted testing based on symptoms or family history.

Testing in Men

Hashimoto's affects men at roughly one-seventh the rate of women, but it does occur. Men often present later because symptoms overlap with androgen deficiency. TSH, free T4, and TPO-Ab remain the appropriate first-line tests regardless of sex. Testosterone levels may warrant checking simultaneously given the bidirectional relationship between thyroid and gonadal hormone axes.

What Happens After a Hashimoto's Diagnosis?

A confirmed diagnosis opens three clinical paths depending on TSH level and symptoms.

Watchful Waiting (Euthyroid Hashimoto's)

Patients with positive antibodies and normal TSH (0.4-4.0 mIU/L) generally do not need medication. Twice-yearly TSH monitoring is standard. Diet modifications, including selenium supplementation at 200 mcg/day, may reduce TPO-Ab titers. A 2010 randomized controlled trial (N=88) published in the Journal of Clinical Endocrinology and Metabolism found that selenium 200 mcg daily reduced TPO-Ab titers by 49.5% vs. 10.1% in the placebo group at 12 months. Selenium supplementation is not an ATA-approved standard of care but is discussed as an adjunct in several European guidelines.

Subclinical Hypothyroidism (TSH 4.0-10.0 mIU/L)

Treatment is individualized. Younger patients with symptoms, women planning pregnancy, and patients with TSH above 7.0-8.0 mIU/L typically start levothyroxine. The standard starting dose is 1.6 mcg/kg body weight daily, adjusted based on repeat TSH at 6-8 weeks.

Overt Hypothyroidism (TSH >10.0 mIU/L)

Treatment with levothyroxine is nearly universal at this level. The goal TSH on treatment is 0.5-2.5 mIU/L for most adults under 60. Older patients or those with cardiovascular disease may tolerate a slightly higher TSH target to avoid overtreatment risks.